{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06411730",
            "orgStudyIdInfo": {
                "id": "IM045-1009"
            },
            "organization": {
                "fullName": "Celgene",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity",
            "officialTitle": "A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-the-safety-tolerability-and-drug-levels-of-orally-administered-bms-in-healthy-participants-healthy-elderly-participants-and-healthy-participants-of-japanese-ethnicity"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-29",
            "studyFirstSubmitQcDate": "2024-05-09",
            "studyFirstPostDateStruct": {
                "date": "2024-05-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celgene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, and drug levels of orally administered BMS-986368 in healthy participants, healthy elderly participants, and healthy participants of japanese ethnicity."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Participants"
            ],
            "keywords": [
                "Pharmacokinetics",
                "Pharmacodynamics",
                "BMS-986368",
                "CC-97489",
                "Healthy Volunteers",
                "Elderly Volunteers",
                "Japanese Volunteers",
                "Multiple Ascending Dose",
                "Healthy Participants",
                "Elderly Participants",
                "Japanese Participants"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 64,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1A",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                },
                {
                    "label": "Cohort 1B",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                },
                {
                    "label": "Cohort 1C",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                },
                {
                    "label": "Cohort 2A",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                },
                {
                    "label": "Cohort 2B",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                },
                {
                    "label": "Cohort 2C",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                },
                {
                    "label": "Cohort 2D",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                },
                {
                    "label": "Cohort 3A",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                },
                {
                    "label": "Cohort 3B",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986368"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BMS-986368",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Cohort 1A",
                        "Cohort 1B",
                        "Cohort 1C",
                        "Cohort 2A",
                        "Cohort 2B",
                        "Cohort 2C",
                        "Cohort 2D",
                        "Cohort 3A",
                        "Cohort 3B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with adverse events (AEs)",
                    "timeFrame": "Up to 44 days"
                },
                {
                    "measure": "Number of participants with serious adverse events (SAEs)",
                    "timeFrame": "Up to 44 days"
                },
                {
                    "measure": "Number of participants with vital sign (VS) abnormalities",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Number of participants with physical examination abnormalities",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Number of participants with electrocardiogram (ECG) abnormalities",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Number of participants with clinical laboratory asssement abnormalities",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Number of participants with treatment-emergent suicidal ideation and behavior through assessment of Columbia Suicide Severity Rating Scale (C-SSRS)",
                    "timeFrame": "Up to 21 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "Up to 16 days"
                },
                {
                    "measure": "Maximum observed plasma concentration (Cmax)",
                    "timeFrame": "Up to 16 days"
                },
                {
                    "measure": "Time of maximum observed plasma concentration (Tmax)",
                    "timeFrame": "Up to 16 days"
                },
                {
                    "measure": "Absolute levels of monoacylglycerol lipase (MGLL) enzymatic activities in peripheral blood mononuclear cells (PBMCs)",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Percent change from baseline for monoacylglycerol lipase (MGLL) enzymatic activities in peripheral blood mononuclear cells (PBMCs)",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Plasma concentrations of anandamide (AEA)",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Percent change from baseline of anandamide (AEA)",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Whole blood concentrations of 2-arachidonoylglycerol (2-AG)",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Percent change from baseline of 2-arachidonoylglycerol (2-AG)",
                    "timeFrame": "Up to 21 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n* Participants must be healthy male or non-pregnant and non-nursing female individuals.\n* For Part 2 only, participants must be of Japanese ethnicity (both biological parents are ethnically Japanese).\n* Participants must have a body mass index (BMI) of 18.0 kg/m2 to 33.0 kg/m2, inclusive.\n* Participants must have normal renal function at screening.\n\nExclusion Criteria\n\n* Participants must not have a personal or first-degree family (individual's parents, siblings, and children) history of clinically significant psychiatric disorder, including, but not limited to, schizophrenia, psychosis, bipolar disorder, panic disorder, generalized anxiety disorder, and obsessive-compulsive disorder.\n* Participants must not have any significant acute or chronic neurological illness (eg, history of intracranial or intraspinal hemorrhage, CNS lesions, recent bacterial or fungal meningitis, etc) as determined by the investigator.\n* Participants must not have a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, peripheral vascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary (GU) abnormalities/diseases including but not limited to peptic ulcer disease, or significant GI bleeding, pancreatitis, hypokalemia.\n* Participants must not have had a SARS-CoV-2 infection within 2 weeks prior to screening.\n* Participants must not have a history of any significant drug allergy or hypersensitivity (such as anaphylaxis or hepatotoxicity).\n* Other protocol-defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clincal.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain the NCT# and Site#",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Anaheim Clinical Trials (ACT)",
                    "status": "RECRUITING",
                    "city": "Anaheim",
                    "state": "California",
                    "zip": "92780",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amina Haggag, Site 0001",
                            "role": "CONTACT",
                            "phone": "714-774-7777"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.83529,
                        "lon": -117.9145
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "See plan description",
            "accessCriteria": "See plan description",
            "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}